ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 601

Hypovitaminosis D and The Metabolic Syndrome In Patients With Systemic Lupus Erythematosus (SLE)

Chi Chiu Mok1, Ling Yin Ho1 and Daniel Birmingham2, 1Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, 2Medicine, Ohio State University Medical Center, Columbus, OH

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Lupus and metabolic syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects I - Renal, Malignancy, Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Low vitamin D level has been linked to cardiovascular diseases and mortality in the general population.  Hypovitaminosis D is associated with certain traditional vascular risk factors in patients with SLE.  This study aims to evaluate the relationship between the metabolic syndrome (MetS) and serum 25-hydroxyvitamin D level in patients with SLE

Methods:

Consecutive patients who fulfilled >=4 ACR criteria for SLE in a two-month period were recruited from our out-patient lupus clinics.  Blood was taken in the morning for the assay of 25-hydroxyvitamin D3 (enzyme immunoassay; Immunodiagnostic Systems Inc, Fountain Hills, AZ, USA) and high sensitivity C-reactive protein (hsCRP) (solid phase chemilluminescence immunometric assay; Siemens Healthcare Diagnostics, Deerfield, Il., USA).  Clinical assessments (waist circumference, fasting glucose and lipid level, blood pressure) were made for each patient who was stratified for the MetS according to the 2009 International joint consensus criteria, using the Asian criteria for abdominal obesity (ref 1).  The relationship between 25-hydroxyvitamin D level and the MetS was studied by linear regression, with adjustment for other confounding covariates.

Results:

257 SLE patients (94% women) were studied.  All were ethnic Chinese.  The mean age was 39.6±13.1 years and SLE duration was 8.3±6.9 years.  Vitamin D insufficiency (25-hydroxyvitamin D3 <30ng/mL), deficiency (25-hydroxyvitamin D3 <15ng/mL, and severe deficiency (level<10ng/mL) was present in 95%, 25% and 3.5% of patients, respectively.  The prevalence of the MetS was 8.3%, 11% and 22.2% in patients with vitamin D insufficiency, deficiency and severe deficiency, respectively.  None of the patients with 25-hydroxyvitamin D3 levels >30ng/mL fulfilled the criteria for the MetS.  Linear regression analysis revealed that levels of 25(OH)vitamin D3 were independently associated with age (Beta 0.19; p=0.002), the presence of the MetS (Beta -0.14; p=0.049) and hsCRP level (Beta -0.14; p=0.04) after adjustment for gender, SLE duration, duration of sunshine in the month of venepuncture, SLE damage scores (SDI), smoking ³3 years, renal insufficiency (estimated CrCl < 50ml/min), photosensitivity and ever use of glucocorticoids.

Conclusion:

Vitamin D deficiency is prevalent in patients with SLE.  Hypovitaminosis D is independently associated with the MetS and hsCRP, suggesting that it is a novel risk factor for vascular thrombosis in patients with SLE.

Ref 1.  Alberti KG et al. Circulation 2009;120:1640–5.


Disclosure:

C. C. Mok,

Pfizer Inc,

8,

GlaxoSmithKline,

8,

Mundipharma Pte Ltd,

9;

L. Y. Ho,
None;

D. Birmingham,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hypovitaminosis-d-and-the-metabolic-syndrome-in-patients-with-systemic-lupus-erythematosus-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology